ILMN Stock Price Today (October 2026) — Illumina, Inc. Analysis & Key Metrics 2026-10-20
Illumina, Inc. (ILMN) is trading at $267.93, up 2.01% today (as of October 2026). The stock continues to show sustained strength above key moving averages, attracting attention from investors looking for Healthcare growth opportunities.
- According to consensus analyst estimates, the 1-year price target is $241.05 (10.0% downside).
- Volatility is high (46.80% annualized), implying wide price swings for short-term traders.
- The fundamental picture, based on the latest financial filings, is nuanced: solid revenue growth (9.40% YoY) alongside competitive pressures in the Diagnostics & Research space.
ILMN Stock Analysis: Key Metrics & Valuation (October 2026)
Concise, actionable data for investors
Illumina, Inc. - Historical Price & Volume
- Price
- Volume
- Latest price
Market Cap
Enterprise Value: $41.82B
P/E Ratio
Forward P/E: 35.04
Revenue Growth
Year over Year
Analyst Target
-10.0% downside from target
Key Investor Questions About ILMN
What investors need to know before buying
Based on current market data, ILMN presents a neutral technical setup with looking solid fundamentals.
- Technicals say: Neutral (RSI 53.91)
- Fundamentals say: Looking solid (debt and growth supportive)
ILMN's growth trajectory depends on its ability to expand within the Diagnostics & Research sector while managing margin pressures.
- Future growth will depend on performance in core Diagnostics & Research operations.
- The ability to manage competitive pressures will be crucial for sustained growth.
The primary risks for ILMN investors include debt exposure and competitive dynamics in the Diagnostics & Research industry.
- $2.53B in debt could be a headwind in a high-rate environment.
- Fierce competition from established players in Diagnostics & Research.
52-Week Trading Range
Over the past year, ILMN stock traded between $94.00 and $309.35 and currently trades near the high end of that range. Big swings are likely unless a major catalyst emerges.
Volatility & Risk Profile
With 46.80% annualized volatility and β=1.07, the stock exhibits moderate correlation to market moves—making ILMN suitable for investors comfortable with active risk management.
Institutional & Insider Ownership
Lower institutional support combined with high short selling points to negative sentiment.
Analyst Sentiment & Price Targets
Latest News & Headlines
Recent headlines, coverage and TickZen analysis
Market news
Illumina To Webcast Upcoming Investor Conference
Should You Be Worried About Tempus AI Stock?
The AI Trade Just Moved Into Your Bloodstream, and 4 Healthcare Stocks Are Winning
Invesco S&P 500 Equal Weight (RSP) Sells Moderna and PTC on Thursday
Latest TickZen Insights
All insights →No TickZen article on ILMN yet. Our newest analysis:
Explore More Analysis for ILMN
Additional research, tools, and technical breakdowns
Stock Analyzer Report
Deep-dive automated research and stock rating report.
DCF Fair Value Calculator
Discounted cash flow model and intrinsic value projection.
AI Price Predictions
Multi-scenario price predictions and consensus targets.
Insider Activity Tracker
Track buying/selling behavior of corporate insiders.
Earnings Calendar
Track upcoming and historical corporate earnings reports.
Market Insights & Research
Read the latest analysis articles and expert research.
Earnings snapshot
Next report Oct 29, 2026 (after the close)
Frequently Asked Questions
Common investor questions about Illumina, Inc.
Illumina, Inc. (ILMN) is currently trading at $267.93. The RSI (14-day) is at 53.9, indicating neutral territory. Wall Street analysts have a consensus "buy" recommendation. The mean analyst price target of $241.05 implies 10.0% downside from current levels. Volatility is high at 46.8% annualized, meaning significant price swings are common. Investors should consider their risk tolerance, investment horizon, and portfolio diversification before making a decision.
Based on current valuation metrics for Illumina, Inc. (ILMN): The trailing P/E ratio is 39.14, which is above the market average, indicating investors are pricing in higher growth expectations. The forward P/E is 35.04, lower than the trailing P/E, suggesting analysts expect earnings improvement. The PEG ratio is 3.23, above 2.0, suggesting the stock may be overvalued relative to its expected growth. Price-to-Book is 11.08. Price-to-Sales is 7.00. Valuation should be compared to Diagnostics & Research industry peers for context, as different sectors trade at different multiples.
Based on 20 analysts covering ILMN, the consensus price target is $241.05. This represents a 10.0% downside from the current price of $267.93. The range spans from a low target of $113.00 to a high target of $365.00, reflecting varying levels of optimism among analysts. The consensus recommendation is "buy". Note: Analyst price targets are forward-looking estimates and not guarantees of future performance.
Illumina, Inc. (ILMN) does not currently pay a regular dividend. The company may be reinvesting profits into growth initiatives, or may not yet be profitable enough to distribute earnings to shareholders.
Key risks for Illumina, Inc. (ILMN) investors include: 1. High volatility (46.8% annualized)—the stock can experience significant daily price swings. 2. Elevated short interest (10.3% of float) suggests significant bearish sentiment. 3. Broader market and macroeconomic risks (interest rates, inflation, geopolitical events). 4. Diagnostics & Research sector-specific competitive pressures. Investors should diversify and consider their risk tolerance before investing.
Here is Illumina, Inc.'s (ILMN) current debt and financial health profile: Total debt stands at $2.53B. The debt-to-equity ratio is 0.89x, which is elevated and warrants monitoring, especially in a rising interest rate environment. The current ratio is 1.80, indicating strong short-term liquidity. The quick ratio is 1.25. The company holds $1.17B in cash and equivalents. Free cash flow is positive at $797.63M, providing a cushion for debt servicing and shareholder returns.